亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in England

SABR波动模型 医学 放射治疗 肺癌 阶段(地层学) 外科 队列 离格 内科学 随机波动 生物 波动性(金融) 金融经济学 古生物学 经济
作者
Aamir Khakwani,Susan Harden,Paul Beckett,David Baldwin,Neal Navani,Douglas West,Richard Hubbard
出处
期刊:Thorax [BMJ]
卷期号:75 (3): 237-243 被引量:18
标识
DOI:10.1136/thoraxjnl-2018-212493
摘要

Approximately 15%-20% of all non-small cell lung cancer (NSCLC) cases present with stage I disease. Surgical resection traditionally offers the best chance of a cure but some patients will not have this treatment due to older age, comorbidities or personal choice. Stereotactic ablative radiotherapy (SABR) has become an established curative intent treatment option for patients who are not selected for or do not choose surgery. The aim of this study is to compare survival at 90 days, 6 months, 1 year and 2 years for patients who received either lobectomy or SABR.We used data from the 2015 National Lung Cancer Audit database and linked with Hospital Episode Statistics and the radiotherapy dataset to identify patients with NSCLC stage IA-IB and performance status (PS) 0-2 who underwent surgery or SABR treatment. We assessed the likelihood of death at 90 days, 6 months, 1 year and 2 year after diagnosis and procedure date to observe survival between two patient groups.We identified 2373 patients in our cohort, 476 of whom had SABR. The median difference between date of diagnosis and date of treatment for surgery patients was 17 days while for SABR patients it was 73 days. Increasing age and worsening PS were associated with having SABR rather than surgery. Survival between the two treatment modalities was similar early on but by 1-year people who had surgery did better than those who had SABR (adjusted ORs 2.12, 95% CI 1.35 to 2.31). This difference persisted at 2 years and when the analysis was restricted to patients aged <80 years and with PS 0 or 1 and stage IA only.Our analysis suggests that patients who have lobectomy have a better survival compared with SABR patients; however, we found considerable delays in patients receiving SABR which may contribute to poorer long-term outcomes with this treatment option. Reducing these delays should be a key focus in development and reorganisation of services.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Yan应助小于采纳,获得20
1秒前
9秒前
17秒前
脑洞疼应助最佳赏味期采纳,获得10
33秒前
达不溜完成签到,获得积分10
34秒前
42秒前
44秒前
50秒前
IfItheonlyone完成签到 ,获得积分10
59秒前
所所应助俊逸小刺猬采纳,获得10
1分钟前
1分钟前
在水一方应助cola采纳,获得30
1分钟前
1分钟前
blenx完成签到,获得积分10
1分钟前
1分钟前
1分钟前
cola发布了新的文献求助30
1分钟前
最佳赏味期完成签到,获得积分10
1分钟前
隐形曼青应助俊逸小刺猬采纳,获得10
1分钟前
1分钟前
hy完成签到 ,获得积分10
1分钟前
CipherSage应助黄金版采纳,获得10
1分钟前
1分钟前
英姑应助享受不良诱惑采纳,获得10
2分钟前
付强发布了新的文献求助10
2分钟前
彭于晏应助付强采纳,获得10
2分钟前
2分钟前
2分钟前
1234567xjy发布了新的文献求助10
2分钟前
绵绵球发布了新的文献求助10
2分钟前
小于发布了新的文献求助20
2分钟前
起风了完成签到 ,获得积分10
2分钟前
科研通AI6应助wF采纳,获得10
2分钟前
2分钟前
田様应助科研通管家采纳,获得30
2分钟前
1234567xjy完成签到,获得积分10
2分钟前
eagle完成签到,获得积分20
2分钟前
付强完成签到,获得积分10
2分钟前
orixero应助绵绵球采纳,获得10
2分钟前
不二完成签到 ,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Encyclopedia of Solid-Liquid Interfaces 600
A study of torsion fracture tests 510
Narrative Method and Narrative form in Masaccio's Tribute Money 500
Aircraft Engine Design, Third Edition 500
Neonatal and Pediatric ECMO Simulation Scenarios 500
苏州地下水中新污染物及其转化产物的非靶向筛查 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4753208
求助须知:如何正确求助?哪些是违规求助? 4097737
关于积分的说明 12678403
捐赠科研通 3810737
什么是DOI,文献DOI怎么找? 2103922
邀请新用户注册赠送积分活动 1129114
关于科研通互助平台的介绍 1006289